FDA Approves New Pancreatic Cancer Drug Rasonque

Why it matters locally: The approval of Rasonque offers a new treatment option for Virginians living with metastatic pancreatic cancer, potentially impacting patients and healthcare providers across the state.

WASHINGTON – The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib) today, introducing a new treatment for metastatic pancreatic cancer. Rasonque functions as a RAS inhibitor, targeting the most common form of the disease. Regulators made the approval several months ahead of their projected schedule. The decision makes Rasonque available to patients with advanced pancreatic cancer.